Colorectal carcinoma is one of the most frequent cancer diseases. For patients with this type of cancer, liver metastases are the main cause of death. Therefore, new therapeutic approaches are urgently needed to improve the outcomes. We found that both mRNA and protein levels of tissue inhibitor of metalloproteinase-3 (TIMP3) were decreased significantly in colorectal cancer tissue when compared with normal mucosa, suggesting that decrease of TIMP3 expression was correlated with malignant behavior of colorectal cancer. We evaluated the power of TIMP3, a new potent multiple functional molecule, as a biotheropeutic tool to treat cancer. Adenovirus-mediated TIMP3 transduction in CT26 colon cancer model demonstrated multiple effects to arrest cancer cell growth and induced massive apoptosis. Also, adenovirally transferred TIMP3 reduced adhesion, migration and invasion behaviors of CT26 cells in vitro. In vivo data showed that TIMP3 suppressed in vivo tumor growth and that liver metastasis was significantly reduced by TIMP3 transduction. This is the first systematic preclinical study to show that TIMP3 may be a potential molecular tool for colon cancer biological therapy.
INTRODUCTION
Colorectal cancer is one of the most common cancer types, ranking the third cause of cancer death and costing 655 000 lives every year worldwide. The fundamental question in colorectal cancer, as well as other malignancies, is the metastasis of cancer cells to distal organs, producing the intractable and lethal lesions. Despite the progress in traditional cancer-treatment strategies, about 50% of the cancer patients will lose their lives 5 years after their first diagnosis. Efforts are now focused on the multi-modality treatments, including biological therapy and gene therapy, in an attempt to improve local control and eliminate micrometastasis.
The molecular mechanism involving colorectal metastasis is not well understood. Currently, colorectal cancer metastasis is viewed as a result of comprehensive consequence of gene mutations, epigenetic deregulation and gene-expression disorders. Many genes have been identified as being involved in migration, adhesion and angiogenesis steps of metastasis process, such as APC, p53 and DCC/SMAD4. 1 Tissue inhibitor of metalloproteinases (TIMPs) are the proteins to anti-act the matrix metalloproteinase (MMP) activity, keeping the balance of TIMPs and MMPs. Among the TIMPs, TIMP3 is demonstrated to be associated with powerful anticancer capacity. Clinical studies reported that TIMP3 was silenced in a number of cancer types. It was also reduced in the stroma surrounding invasive colorectal cancers. 2 Reduced expression of TIMP3 was significantly associated with nodal involvement. 3 Overexpression of TIMP3 in tumor cell lines blocks cancer cell invasion and metastasis, as well as growth. 4, 5 Qi et al. 6 demonstrated the ability of TIMP3 to inhibit VEGF-mediated angiogenesis independent of MMP-inhibitor activity. Recently, TIMP3 was found to be a multiple functional molecule in many aspects of physiology and disease development. 7, 8 These reports highlighted the importance of TIMP3 in tumor advancement and its significance in cancer biotherapy.
Based on the multifunctional property of TIMP3 in suppressing cancer and high capacity of colon cancer to invade surrounding tissue and metastases to distant organs (especially liver), we assayed the preclinical efficacy of TIMP3 by adenoviral vector as a biotherapeutic agent in highly metastatic colon cancer cell model CT26 in vitro and in vivo. Till now, no systematic therapeutic evaluation of TIMP3 in colon cancer has been performed.
MATERIALS AND METHODS

Tissue array and immunochemistry assay
The tissue array containing tumor samples from 40 cases was constructed and reviewed by two independent pathologists. We got the informed consent from the patients who received the colon tumor removal in the Department of Abdominal Surgery, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, from August 2004 to October 2004. The tissue array was immunnohistochemically stained as described previously. 9 Cytoplasmic TIMP3 staining was evaluated using Medical Image Analysis System (BUAA, Beijing, China). Two vision fields were randomly scanned in each tissue spot and the integral optical density of stained immunohistochemical-positive area was measured.
The TIMP3 antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). This part of the experiment was approved by the Institute Ethical Committee of the institution. The Declaration of Helsinki protocols were followed, and the consent was recieved from the patients in written form.
Cell line culture
The mouse colon cancer cell line CT26 was cultured in 5% CO 2 at 37 1C in RPMI 1640 medium, completed with 10% fetal bovine serum, 100 U ml À 1 penicillins and 100 mg ml À 1 streptomycin.
Recombinant adenovirus and antibodies
The adenovirus carrying TIMP3 was constructed as described previously. Trypan blue dye exclusion assay for assessing cell viability A total of 8 Â 10 4 CT26 cells were seeded in a 24-well plate and incubated overnight. Ad-TIMP3 or Ad-Null at various MOI (50-400 MOI) were added to the well. After 72 h, the cell viability was determined by trypan blue dye exclusion assay. The experiment was performed three times independently.
Cell-adhesion assay 
Migration and invasion assay
Migration assay was performed using 6.5 mm-diameter transwell chambers (Corning Costar, Cambridge, MA, USA) with polycarbonate membrane inserts (8 mm pore size). The invasion chamber was identical to the migration chamber, but with a 250 mg ml À 1 Matrigel (BD Biosciences) precoated polycarbonate membrane. For both assays, the chambers were placed in 24-well plates containing 1 ml 10% fetal bovine serum serumcompleted RPMI 1640 medium per well. Ad-TIMP3-or Ad-Null-infected CT26 cells (2 Â 10 5 per well) were added to the upper chamber with RPMI 1640 medium containing 2% fetal bovine serum, followed by an incubation for 16 (migration assay) or 18 h (invasion assay) at 37 1C in a 5% CO 2 incubator. Three independent experiments were performed for each set. Then, the cells that had moved and adhered to the lower side of the membrane were fixed and stained with crystal violet. The cells that had migrated to the lower side of the membrane were reviewed under a microscope. For each well, five fields were chosen (the ones in the middle, at 3, 6, 9 and 12 time clock positions) to count the total cell numbers. Data from three parallel wells were averaged and compared between the groups.
Gelatin zymography
Forty-eight hours after Ad-TIMP3 infection, conditional medium was collected and aliquots normalized for varying cell numbers were subjected to zymography as described previously. 9 Tumor xenografts in BALB/c mice For the tumor-formation assay, the CT26 cells were treated with 25 MOI of Ad-TIMP3 or Ad-Null, and then implanted into the right flank of the mice (five mice per group). When the tumors can be felt by touching, their volumes were measured and recorded to plot the growth curve. Data were statistically analyzed for the difference of the tumors between groups. Fifteen BALB/c mice of 6-8 weeks old weighing 18-20 g were injected with 5 Â 10 4 CT26 cells per mouse at the right flank. When the tumors grew to 5 Â 5-mm 2 volume, they were randomly divided into three groups (five mice per group) and were intratumorally injected with saline, Ad-Null and Ad-TIMP3 viruses, respectively at the amount of 1 Â 10 9 PFU for three times (once a day for 3 consecutive days). The tumors were measured every 3 days. The tumor volumes were calculated as V ¼ (p/6)a Â b 2 . The mice were killed at day 21 after tumor inoculation. The tumors were removed and weighed. The tumor-suppressing rate was calculated as: suppressing rate ¼ (tumor weight of control group À tumor weight of treatment group)/tumor weight of the control group Â 100%.
For the establishment of the colon cancer metastatic model, 18 BALB/c mice were randomized into three groups (six mice per group). The variously treated CT26 cells (blank control cells, Ad-Null-and Ad-TIMP3-infected cells (25 MOI of infection)) were surgically injected into the spleen (1 Â 10 5 cells) under anesthesia. Seven days after cancer cell implantation, the mice were killed and the livers were removed and fixed by 4% formalin. The liver samples were cut into slices in every 1.5 mm at maximum cross-section. At the maximal cross-section, two slides at a 1-mm interval were reviewed for the number of metastatic lesions for each mouse (12 slides in total for each group). This animal experiment was approved by the Institutional Animal Care and Use Committee and was in compliance with all regulatory guidelines.
Statistical analyses
The data were analyzed by t-test or one-way analysis of variance. The statistical analysis was performed using SPSS version 11.0 software (Chicago, IL, USA), and Po0.05 was considered significant.
RESULTS
TIMP3 expression is shut off in colon cancers RT-PCT was used to detect the expression of TIMP3 in six colon cancers and paired normal mucosal tissues. In the normal mucosal tissue, TIMP3 mRNA was expressed at certain levels. However, it was weakly expressed or totally lost in the colon cancer tissue from the same patients (Figure 1a) . At the protein level, TIMP3 also was downregulated in the cancer tissues compared with normal colon mucosa (Figure 1b) . This indicated that TIMP3 activity was shut off at the transcriptional level during carcinogenesis.
TIMP3 expression in colon cancer tissue array Tissue array containing samples from 40 colon cancer tissues and 40 normal control tissues was constructed and TIMP3 expression at protein level was immunohistochemically detected. In the normal mucosal tissues, TIMP3 protein expression was abundant in cytoplasm but absent from the cancer tissues (Figure 1c) . Notably, TIMP3 is downregulated in the front edge of normal tissue surrounding cancer. Quantitative analysis of TIMP3 staining TIMP3 transfer inhibits clone cancer H Lin et al was carried out and the integral optical density was significant different between normal and cancer tissues (Po0.05) (Figure 1d ).
Ad-TIMP3 induced cell apoptosis and suppressed CT26 growth The TIMP3-carrying adenovirus was constructed previously as described. 5 CT26 cells were infected with Ad-TIMP3 at 50-400 MOI. From Figure 2 , the expression of TIMP3 mRNA and protein gradually increased at 48 h after transfection (Figures 2a and b) .
There was a clue that TIMP3 may exhibit pro-apoptotic properties in corneal stromal cells. 1 We detected whether Ad-TIMP3 works on colon cancer cells through inducing apoptosis. From Figure 2b , poly ADP-ribose polymerase (PARP) cleavage was increasingly obvious in Ad-TIMP3-treated cells, which indicated that TIMP3 transfer induced apoptosis of CT26 cells. Moreover, annexin V-FITC/ PI staining assay showed that Ad-TIMP3 induced apoptosis increasingly with the dose of infection. At 400 MOI of Ad-TIMP3, 460% cells underwent apoptosis (Figure 2c) .
To evaluate the effect of Ad-TIMP3 on cell growth, we performed trypan blue dye exclusion assay at 72 h after Ad-TIMP3 infection. Comparing with control, the cell growth was significantly inhibited by Ad-TIMP3 infection. At 400 MOI of infection, only 2.4 Â 10 5 cells were left alive (30.38%), whereas Ad-Null did not exert much effect on cell growth, indicating a growthsuppressing effect of TIMP3 on cancer cells (Figure 2d ).
TIMP3 inhibited MMP2 and MMP9 activity
As an inhibitor of MMP activity in vivo, TIMP3 targets MMP2 and MMP9 to block the invasion and metastasis of cancer cells. We detected the role of Ad-TIMP3 to suppress MMP2 and MMP9 activity in vitro. By gelatin zymography assay, Ad-TIMP3 infection decreased the MMP2 and MMP9 activities in the culture supernatant in a dosedependent manner. There was even no MMP2 activity visible in the gel when 400 MOI Ad-TIMP3 was used (Figure 2e ).
Ad-TIMP3 decreased adhesion ability of CT26 cells and impaired the migrative and invasive potential of CT26 cells
One of the key steps of cancer metastasis is the adhesion of cancer cells to the vascular wall and stroma. The Matrigel resembles the property of tissue matrix. We used Matrigel-coated plates to evaluate the effects of Ad-TIMP3 on cancer cell adhesion to the matrix. Control adenovirus vector did not exert any effect on cell adhesion, whereas Ad-TIMP3 significantly decreased cell adhesion to Matrigel at 50 MOI (Figure 3a) .
Migration and invasion are additional aspects of cancer cell behavior, implying cancer metastasis potential. We evaluated the migration and invasion ability of the colon cancer cell line after Ad-TIMP3 infection using transwell chamber. The percentage of cells moving to the other side of the 8-ml-pore polycarbonate membrane reflects the migration ability of the cells, while when the membrane is coated with Matrigel (extracellular matrix), it reflects the cells' invasion ability. With the increase of Ad-TIMP3 infection intensity, there were less cells moving through the membrane to the other side (Figures 3b and c) . Compared with vector control, the migration percentages of the cell at 50, 100, 200 and 400 MOI were decreased by Ad-TIMP3, respectively. In terms of invasion ability, Ad-TIMP3 also significantly reduced the percentage of cells penetrating the membrane.
Ad-TIMP3 suppressed the tumor formation and growth in BALB/c mouse model To answer whether TIMP3 is capable of suppressing the tumor formation in vivo, we treated the CT26 cells with Ad-TIMP3 at 25 MOI and implanted the cells into the right flank of the BALB/c mice. Tumor formation and their volumes were recorded regularly. At the end point, the Ad-TIMP3-treated cells formed tumors much smaller than that of control groups, showing the tumor-suppressing potential in cancer cells (Figures 4a and b) .
To explore the therapeutic value of TIMP3 on tumor growth in vivo, we performed experimental treatment of tumor model in 
TIMP3 transfer inhibits clone cancer H Lin et al
nude mice by intratumoral Ad-TIMP3 injection. At the end of the experiment, the tumor-weight inhibition rate was up to 52.5% (Figures 4c and d) . From the ninth day after treatment, the tumor volume of Ad-TIMP3 treatment group was significantly lower than the other two control groups (Po0.05), confirming the growthinhibitive effect of TIMP3 in vitro.
Ad-TIMP3 suppressed the in vivo migration of CT26 in BALB/c mouse model To investigate the activity of TIMP3 on cancer metastasis, we infected the CT26 cells by Ad-TIMP3, and then injected them into the tail of spleen by surgery. The injected cells would move to the liver and settle down to form metastatic lesions if they were Figure 2 . Ad-TIMP3 induced cell apoptosis and suppressed cell growth. (a) TIMP3 mRNA expression was gradually upregulated with increased MOI after Ad-TIMP3 infection, whereas TIMP3 was not detectable by RT-PCR in control CT26 cells. The fold change of TIMP3 mRNA expression relative to that of 50 MOI infection was calculated. (b) By Ad-TIMP3 infection, TIMP3 protein was increased at a dose-dependent manner. To show the exogenous TIMP3-induced apoptosis, we detected the PARP cleavage. It showed the PARP cleavage occurred with the intensity of Ad-TIMP3 infection. (c) CT26 cells were transfected by Ad-TIMP3 or Ad-Null at the indicated MOI for 72 h and then subjected to annexin V-FITC assay. Percentage of apoptosis was defined by % of cells that were FITC þ /PI À and FITC þ /PI þ . The experiment was performed twice independently; (d) CT26 cells were infected with Ad-TIMP3 or Ad-Null at the indicated MOI for 72 h. Trypan blue exclusion was used to determine cell number (compared with Ad-Null, *Po0.05). (e) Ad-TIMP3 infection suppressed the activity of MMP2 and MMP9 in the culture supernatant. In the gelatin zymography assay, MMP2 and MMP9 activity was suppressed in a dose-dependent manner by Ad-TIMP3. Table 1 ). Compared with vector control group, Ad-TIMP3 suppressed 93.8% of the lesions. This experiment indicated that TIMP3 was powerful to inhibit the in vivo cancer metastasis.
DISCUSSION
Colon cancer has been one of the most common cancer types worldwide. The strategies to treat colon cancer are still limited to surgery and chemotherapy, and on some occasions, radiotherapy.
As a developing strategy, biotherapy is emerging to be the most promising addition to the current treatment.
TIMP3 is an enzyme that in human is encoded by Timp3 gene. TIMP3 is a member of TIMP gene family and functions to inhibit MMPs, which contribute to cancer progress by degrading the extracellular matrix. Recent studies have revealed that TIMP3 also has tumor-suppressing roles through promoting apoptosis, 7 inhibiting lymphogenesis and angiogenesis 10, 11 and interfering response of cancers to anticancer drugs.
12
CT26 is a highly metastatic cancer cell model usually used to evaluate the antimetastatic potential of various therapeutic agents. It is not easy to block the metastasis process in the cell model. Here we used the CT26 cell line to evaluate the biotherapeutic effects of TIMP3. When delivered by adenoviral vector, TIMP3 was potent to suppress cancer behaviors, including induction of apoptosis and inhibition of cell migration and invasion and so on. In this study, we first reported the potential value of TIMP3 in colon cancer biotherapy. TIMP3 not only suppressed the local growth of cancer but also greatly decreased the chance of liver metastasis.
We did not focus on the molecular pathways regulated by TIMP3, but on the biological consequence in conquering colon cancer metastasis. We found that TIMP3 is lowly expressed in cancer and the front edge of normal tissue surrounding cancer. It has been reported the downregulation of TIMP3 in cancers was associated with excessive methylation on the promoter region. 13 Dysregulation of MMP enzymes leads to increased extracellular matrix turnover, which is a key step for the local invasion and metastasis of many tumors. TIMPs limit the activity of MMPs, suggesting their use in cancer biotherapy. TIMP-1 and -2 inhibit cancer cell invasion, whereas TIMP3 uniquely both inhibits cancer cell invasion and promotes apoptosis, bearing advantages to be used in cancer gene therapy.
14 In addition, TIMP3 has bystander effects on untransfected cells. Overexpression of TIMP3 induced apoptosis in lung cancer cells and upregulated the expression of p53, Fas-ligand, TNFR1 and TNFR2, facilitating its cancer therapeutic effects. 15 In our study, we found that TIMP3 was significantly downregulated in colon cancer tissues. In vitro studies showed that exogenous expression of TIMP3 induced cancer cell apoptosis, growth arrest, as well as migration and invasion inhibition. In vivo studies demonstrated that Ad-TIMP3 suppressed tumor growth and distal metastasis. This study is the first to describe downregulation of TIMP3 in colon cancer and its value as a potential tool in colon cancer biotherapy. TIMP3 is recognized as a multifunctional molecule in cell biology, covering cell differentiation, angiogenesis and immunology. 8, 16, 17 It has been reported that TIMP3 was involved in cancer apoptosis and invasion. In terms of the status of TIMP3 in cancer, it is also found downregulated in 95.2% clear renal cell carcinoma. 18 In esophageal squamous cell carcinoma, hypermethylation contributes to downregulation of TIMP3.
19
TIMP3 induces apoptosis through both the caspase-dependent and caspase-independent pathways. 20 In our study, Ad-TIMP3 induced apoptotic morphology in cancer cells. Overexpression of TIMP3 induces release of cytochrome-c and activates the caspase-8 and caspase-9 pathways, both resulting in cancer cell apoptosis. 21 Bond et al. 21 reported that TIMP3 induces apoptosis through a Fas-associated death domain-dependent type II apoptotic pathway. On the other hand, Kallio et al. 20 showed that TIMP3 is capable of inducing apoptosis in the absence of caspase-8 activation in human small cell lung carcinoma cells, suggesting other pathways besides death receptor signaling. Our previous study also showed that Ad-TIMP3 induced p53 expression in human cancer cell lines Hela and Caski. 5 This fact indicated that TIMP3 may induce apoptosis indirectly through the p53 pathway. As well known, p53 is a multifunctional molecule in causing apoptosis via several pathways.
Highly active MMPs inhibitors are promising strategies to block cancer invasion and metastasis. Though some artificial MMP inhibitors have been synthesized and are being evaluated in clinical trials, such as AG3340, CGS27023A and BAY12-9566, none of them have been manifested to be effective for cancer patients in advanced stage. [22] [23] [24] In this study, we testified the cancerinhibiting effects of TIMP3, providing an alternative for comprehensive treatment strategy by its nature of multiple functions in suppressing cancer development.
